Intravenous immunoglobulin-induced acute thrombocytopenia
| Autor: | Boaz Tadmor, Pia Raanani, Galia Spectre, Lilach Bonstein, Nardeen Atweh, Anna Gurevich-Shapiro, M. Shapiro, Tsipora Gruenewal |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
biology
business.industry medicine.drug_class Immunology Hematology 030204 cardiovascular system & hematology Monoclonal antibody medicine.disease Thrombocytopenic purpura Hypogammaglobulinemia 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Antigen hemic and lymphatic diseases 030220 oncology & carcinogenesis biology.protein Immunology and Allergy Medicine Platelet Splenic marginal zone lymphoma Antibody business B cell |
| Zdroj: | Transfusion. 58:493-497 |
| ISSN: | 0041-1132 |
| DOI: | 10.1111/trf.14419 |
| Popis: | Background Intravenous immunoglobulin (IVIG) has known efficacy in various hematologic conditions, including immune thrombocytopenic purpura. Study design and methods We present the clinical course of a patient with splenic marginal zone lymphoma, who developed acute thrombocytopenia on three consecutive episodes, with nadir counts of 27 × 109 , 50 × 109 , and 9 × 109 /L, upon administration of Intratect IVIG for hypogammaglobulinemia. An immunofluorescence test applying flow cytometry and monoclonal antibody immobilization of platelet antigens (MAIPA) assay were used to evaluate the reaction between IgG present in the IVIG preparations and the patient's or healthy donors' platelets (PLTs). Results A strong direct binding reaction was observed between the patient's PLTs and Intratect IgG using both methods. A similar reaction failed to materialize with controls. Binding was not antigen specific according to MAIPA. Conclusions This is the first reported case of thrombocytopenia as a possible adverse effect of IVIG. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text